SARS-CoV-2 Clinical Trial
Official title:
Study of Clinical, Biological and Genetic Prognostic Factors of SARS-CoV-2 Infection in Patients Admitted in the Strasbourg University Hospitals
COVID-19 is an emerging disease, for which no specific treatment options are currently
available. Since the end of February 2020, and due to a SARS-CoV-2 superspreading event
(religious meeting), the Strasbourg University Hospital (HUS) had faced a sudden increase of
the number of COVID-19-positive patients in serious condition requiring hospitalization. At
the same time, many people develop only mild or moderate symptoms. To date, the prognostic
factors for the course of SARS-CoV-2 infection are unknown. The primary purpose of the
"COVID-HUS" protocol is to investigate viral and host-related factors to understand the
pathophysiology of COVID infection and to open the way for new diagnostic, prognostic and
therapeutic strategies against SARS CoV-2 .
The secondary objectives are
- Monitoring of viral replication of SARS-CoV-2 in the blood and respiratory tract in
infected patients
- Monitoring of the humoral and cellular response directed against SARS-CoV-2
- Identification of factors leading to significant and / or prolonged viral replication of
SARS-CoV-2 in the blood or respiratory samples
- Evaluation of the benefit of possible treatments implemented following the diagnosis of
SARS-CoV-2 infection
- Exploration of the B and T immune repertoire sequences targeting SARS-CoV-2 in infected
patients
- Typing of the HLA system in infected patients
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT06039449 -
A Study to Investigate the Prevention of COVID-19 withVYD222 in Adults With Immune Compromise and in Participants Aged 12 Years or Older Who Are at Risk of Exposure to SARS-CoV-2
|
Phase 3 | |
Completed |
NCT04512079 -
FREEDOM COVID-19 Anticoagulation Strategy
|
Phase 4 | |
Completed |
NCT04527471 -
Pilot Study of Ensifentrine or Placebo Delivered Via pMDI in Hospitalized Patients With COVID-19
|
Phase 2 | |
Recruiting |
NCT05584202 -
Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in Infants
|
Phase 2 | |
Completed |
NCT04579549 -
Repeat Testing for SARS-CoV-2
|
N/A | |
Active, not recruiting |
NCT05547243 -
A Cohort Study of COVID-19 mRNA Vaccine, Bivalent in Participants in China
|
N/A | |
Recruiting |
NCT04747574 -
Evaluation of the Safety of CD24-Exosomes in Patients With COVID-19 Infection
|
Phase 1 | |
Recruiting |
NCT04613310 -
PCR and Rapid Diagnostic Test on Saliva and Nasopharyngeal Swabs for the Detection of SARS-CoV-2 (COVID-19)
|
N/A | |
Completed |
NCT04515147 -
A Dose-Confirmation Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19
|
Phase 2 | |
Terminated |
NCT04447404 -
DUR-928 in Subjects With SARS-CoV-2 With Acute Lung, Liver or Kidney Injury
|
Phase 2 | |
Withdrawn |
NCT04388709 -
Interferon Lambda Therapy for COVID-19
|
Phase 2 | |
Active, not recruiting |
NCT05550142 -
A Preliminary Exploratory Cohort Study of SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine in Participants Aged 18 Years and Over in China
|
N/A | |
Completed |
NCT04620798 -
Longitudinal COVID-19 Antibody Testing in Indiana University Undergraduate Students
|
N/A | |
Active, not recruiting |
NCT05547256 -
A Preliminary Exploratory Cohort Study of COVID-19 mRNA Vaccine, Bivalent in Participants Aged 18 Years and Over in China
|
N/A | |
Completed |
NCT04561102 -
Evaluation of the COVIDSeq Test in Nasal Swab and Saliva From a COVID-19 Asymptomatic Population
|
||
Completed |
NCT04452604 -
Multicentric Registry of Patients With Acute Leukemia Infected by COVID-19
|
||
Completed |
NCT05366322 -
A Study to Compare mRNA-1273 Versus BNT162b2 COVID-19 Vaccines Among Immunocompromised Adults
|
||
Completed |
NCT04526769 -
Detecting SARS-CoV-2 in Tears
|
||
Terminated |
NCT04958304 -
Moderna COVID-19 Vaccine mRNA-1273 Observational Pregnancy Outcome Study
|
||
Completed |
NCT04690413 -
NOWDx Test for the Detection of Antibodies to COVID-19
|
N/A |